J&J joins the combo lineup at Bristol-Myers, where a new wagon master runs oncology R&D
J&J is taking an immuno-oncology drug licensed in from Aduro and matching it with Bristol-Myers Squibb’s pioneering checkpoint drug Opdivo in the latest example of the tsunami of I/O combo studies taking shape off the coast of the global R&D industry. The move comes one day after Bristol-Myers $BMY tapped a veteran player to take the head of its rapidly growing oncology development operations.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.